1a:I[76881,["/_next/static/chunks/34vbetli0wcl8.js","/_next/static/chunks/3r-sv9fihs3dl.js","/_next/static/chunks/1iw-1573su13p.js","/_next/static/chunks/1z4pd8ibn4l9o.js","/_next/static/chunks/25s0hn3a8-i7k.js","/_next/static/chunks/1hgqrukqn6f-4.js"],"default"] 1c:I[60790,["/_next/static/chunks/34vbetli0wcl8.js","/_next/static/chunks/3r-sv9fihs3dl.js","/_next/static/chunks/1iw-1573su13p.js","/_next/static/chunks/1z4pd8ibn4l9o.js","/_next/static/chunks/25s0hn3a8-i7k.js","/_next/static/chunks/1hgqrukqn6f-4.js"],"default"] 1d:I[91915,["/_next/static/chunks/34vbetli0wcl8.js","/_next/static/chunks/3r-sv9fihs3dl.js","/_next/static/chunks/1iw-1573su13p.js","/_next/static/chunks/1z4pd8ibn4l9o.js","/_next/static/chunks/25s0hn3a8-i7k.js","/_next/static/chunks/1hgqrukqn6f-4.js"],"default"] 1e:I[2116,["/_next/static/chunks/34vbetli0wcl8.js","/_next/static/chunks/3r-sv9fihs3dl.js","/_next/static/chunks/1iw-1573su13p.js","/_next/static/chunks/1z4pd8ibn4l9o.js","/_next/static/chunks/25s0hn3a8-i7k.js","/_next/static/chunks/1hgqrukqn6f-4.js","/_next/static/chunks/1m2y8laff9th9.js"],"default"] 1f:I[33979,["/_next/static/chunks/34vbetli0wcl8.js","/_next/static/chunks/3r-sv9fihs3dl.js","/_next/static/chunks/1iw-1573su13p.js","/_next/static/chunks/1z4pd8ibn4l9o.js","/_next/static/chunks/25s0hn3a8-i7k.js"],"IconMark"] 1b:T52c,

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury.

It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT.

CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

No Dividend Data Available